LungLife AI, Inc.
(the "Company" or "LungLife")

Publication of Annual Report and Accounts & Notice of AGM

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now available on the Company's website and have been posted to those shareholders who have opted out of electronic communications.

The documents are available here: https://investors.lunglifeai.com/

The Company's AGM will be held at 3:00 P.M. (BST) on 4 May 2023, at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP. The Board will make arrangements for shareholders to listen to proceedings remotely should they wish to do so. The Company will announce details of how to listen to the meeting remotely and any other significant changes to the meeting arrangements via RNS and on LungLife's website at https://investors.lunglifeai.com/

Shareholders are strongly encouraged to vote by proxy, whether or not they plan to attend the Company's AGM in person. Shareholders may register their votes on the resolutions of the AGM by completing and returning the Form of Proxy that accompanies the Notice of AGM in accordance with the instructions printed on the Form of Proxy.

Where shareholders hold Common Shares by way of dematerialised depository interests representing underlying Common Shares ("Depository Interests"), they can vote through the CREST system or by returning a Form of Direction to the Company's agent, Link Group. Further instructions are set out in the Notes to the Notice of AGM.

The resolutions to be proposed at the AGM are summarised in the Notice of AGM.

The results of voting on the resolutions will be announced via a regulatory information service and posted on the Company's website as soon as practicable possible after the AGM.

For further information please contact:

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer.  Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.